Sugi Predict

Sugi Predict / Compounds / SCHEMBL4473071

SCHEMBL4473071

SCHEMBL4473071

CC(O)CNC(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ HTT P42858 1/20 0.55
▸ CTSS P25774 3/20 0.54
▸ CTSL P07711 2/20 0.54
▸ CTSK P43235 3/20 0.53
▸ SYK P43405 1/20 0.53
▸ CTSB P07858 1/20 0.53
▸ ATM Q13315 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ HSD17B10 Q99714 1/20 0.50
▸ MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6216286 1.00 LMNA (0.58) LMNASMN1; SMN2HTTCTSSCTSL
SCHEMBL5640402 1.00 LMNA (0.58) LMNASMN1; SMN2HTTCTSSCTSL
SCHEMBL27268626 0.89 LMNA (0.54) LMNASMN1; SMN2HTTCTSSCTSL
SCHEMBL9293928 0.89 LMNA (0.59) LMNASMN1; SMN2HTTCTSSCTSL
SCHEMBL24334713 0.87 HTT (0.57) LMNASMN1; SMN2HTTCTSSCTSL
SCHEMBL9740853 0.87 MEN1 (0.50) LMNASMN1; SMN2CTSSCTSL
SCHEMBL5019087 0.87 LMNA (0.61) LMNASMN1; SMN2HTTCTSSCTSL
SCHEMBL14019069 0.87 LMNA (0.66) LMNASMN1; SMN2HTTCTSSCTSL
SCHEMBL7011949 0.86 LMNA (0.56) LMNASMN1; SMN2HTTCTSSCTSL
SCHEMBL4430839 0.86 LMNA (0.56) LMNASMN1; SMN2HTTCTSSCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117285486-A Synthesis method of 4- (1-aminopropyl-2-yl) piperazine-1-carboxylic acid tert-butyl ester 南通敏言生物医药科技有限公司 2023-12-26 — — CN claimed
CN-117285486-A Synthesis method of 4- (1-aminopropyl-2-yl) piperazine-1-carboxylic acid tert-butyl ester 南通敏言生物医药科技有限公司 2023-12-26 — — CN disclosed
CN-117285486-A Synthesis method of 4- (1-aminopropyl-2-yl) piperazine-1-carboxylic acid tert-butyl ester 南通敏言生物医药科技有限公司 2023-12-26 — — CN disclosed
WO-2023224963-A1 DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS ARIA PHARMACEUTICALS, INC. (US) 2023-11-23 — — WO disclosed
US-20210283132-A1 DIARYLPYRAZOLE COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF SHENZHEN TARGETRX, INC. (CN) 2021-09-16 — — US disclosed
CN-112969698-A Chemical compound 葛兰素史密斯克莱知识产权发展有限公司 2021-06-15 — — CN disclosed
EP-3816162-A1 DIARYLPYRAZOLE COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF Shenzhen TargetRx, Inc. (CN) 2021-05-05 — — EP disclosed
CN-107922423-B Nitrogen-containing tricyclic derivatives having HIV replication inhibiting effect 盐野义制药株式会社 2020-10-27 — — CN disclosed
CN-111138458-A Nitrogen-containing tricyclic derivatives having HIV replication inhibiting effect 盐野义制药株式会社 2020-05-12 — — CN disclosed
WO-2020011141-A1 DIARYLPYRAZOLE COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2020-01-16 — — WO disclosed
US-6403830-B2 A S-(2-(1-IMINOETHYL)AMINO)ETHYL)-2-METHYL-L-CYSTEINE AND SALTS PHARMACIA CORPORATION 2002-06-11 — — US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 — — EP disclosed
US-20020019563-A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors PHARMACIA LLC 2002-02-14 — — US disclosed
WO-2001072703-A1 AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS PHARMACIA CORPORATION (US) 2001-10-04 — — WO disclosed
WO-2001072702-A2 AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS PHARMACIA CORPORATION (US) 2001-10-04 — — WO disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 — — WO disclosed
EP-0463998-B1 Immunological detection of triasulfuron CIBA GEIGY AG (CH) 1997-01-15 — — EP disclosed
US-5563074-A ANTIBODY SPECIFIC TO SULFONYLUREA HERBICIDE CIBA-GEIGY CORPORATION (US) 1996-10-08 — — US disclosed
US-5359135-A Detection in soil, water, air by preferential affinity to monoclonal antibodies CIBA-GEIGY CORPORATION (US) 1994-10-25 — — US disclosed
EP-0463998-A2 Immunological detection of triasulfuron CIBA-GEIGY AG (CH) 1992-01-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210283132-A1 DIARYLPYRAZOLE COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF BRAF, NRAS, MAP2K5 LMNA 4080/4885SMN1; SMN2 2710/4885HTT 2476/4885
US-20020019563-A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors NOS2, NOS1, NOS3 LMNA 3830/4885SMN1; SMN2 2849/4885HTT 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.